Working… Menu

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00257478
Recruitment Status : Completed
First Posted : November 23, 2005
Last Update Posted : June 7, 2012
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc

Brief Summary:
A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Cancer of Prostate Prostatic Cancer Cancer of the Prostate Drug: YM155 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Actual Study Completion Date : March 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed prostate cancer.
  • Prior chemotherapy regimen for prostate cancer

Exclusion Criteria:

  • History of other malignancy in the last 5 years
  • Major surgery within the past 21 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00257478

Layout table for location information
United States, Arizona
Tuscon, Arizona, United States, 85724
United States, California
Los Angeles, California, United States, 90033
United States, Idaho
Coeur d'Alene, Idaho, United States, 83814
United States, New York
Bronx, New York, United States, 10461
New York, New York, United States, 10016
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19111
United States, Texas
San Antonio, Texas, United States, 78229
Amsterdam, Netherlands
United Kingdom
Sutton, Surry, United Kingdom, SM2 5Pt
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma US, Inc.
Layout table for investigator information
Study Director: D. Buell, MD Astellas Pharma US, Inc.

Layout table for additonal information Identifier: NCT00257478     History of Changes
Other Study ID Numbers: 155-CL-007
First Posted: November 23, 2005    Key Record Dates
Last Update Posted: June 7, 2012
Last Verified: June 2012
Keywords provided by Astellas Pharma Inc:
Treatment Efficacy
Treatment Effectiveness
Disease Management
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases